21 hours ago
1
Md Saiful Islam Khan/iStock via Getty Images
Incannex Healthcare (ICXL) lost ~13% on Wednesday even as the company announced that its lead candidate, IHL-42X, succeeded in a mid-stage trial for patients with obstructive sleep apnea, a sleeping disorder characterized by snoring.
Citing topline data from its RePOSA
© FBT Company 2025. All rights are reserved
English (US) ·